Physicians worldwide are welcome to refer patients to City of Hope. When you refer your patient, you can do so with the utmost confidence that our staff will provide the best care possible.
City of Hope has an enduring commitment to continuing medical education, sharing advances in cancer research and treatment with the healthcare community through conferences and symposia.
We provide an innovative series of educational programs for nurses, radiation therapists, pharmacists, cancer researchers and others.
City of Hope offers a range of valuable programs and training for postdoctoral trainees, medical professionals and our own staff.
The aggressive pursuit to discover better ways to help patients now - not years from now - places City of Hope among the worldwide leaders in administering clinical trials.
When Shawn Ahdoot went to donate blood almost 10 years ago, he had no idea that it would change his life forever. Here are five reasons you, too, should become a bone marrow donor.
Linda Malkas, Ph.D., deputy director of basic research for City of Hope who holds the M.T. & B.A. Ahmadinia Professorship in Molecular Oncology, has been appointed to the governing board of the California Institute for Regenerative Medicine (CIRM), the state’s stem cell agency.
CAR-T cell therapy research at City of Hope is an innovative and promising approach that recruits the body’s own immune system in the fight against some of the hardest-to-treat cancers, including multiple myeloma.
Hypercalcemia (high blood calcium), renal problems, anemia and bone problems, also known by the acronym, C.R.A.B. — reflects the typical symptoms of multiple myeloma. City of Hope follows a multiple myeloma patient, Donna McNutt, who finds ways to cope with her diagnosis.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, today announced three new members to its board of directors: Barbara Bruser, senior managing director with First Republic Private Wealth Management, Steven B. Fink, former chief executive officer of Lawrence Investments LLC, and William J. Post, chairman of the board of Translational Genomics Research Institute (TGen).